No Big Ripple for Merck Vioxx Verdict
Updated from 4:30 p.m. EDT
Merck (MRK) confirmed Wednesday that it won an appeal in a liability case related to Vioxx.
A Texas appeals court overturned a verdict that had awarded $7.75 million to the widow of a 71-year-old heart attack victim. Leonel Garza had died after taking Vioxx for a month.
The drug was pulled from the market in 2004 after research showed it increased the risk of heart attack and stroke.The jury's original verdict on April 21, 2006, included $7 million in compensatory damages and $25 million in punitive damages for a total of $32 million against Merck, the company said in a statement. In December of that year, the punitive award was reduced to $750,000 in compliance with Texas statutory caps. Fordham Law professor Ben Zipursky, who specializes in product liability law in the pharmaceutical industry, said it's important to realize this was a very weak case. Aside from the risk factors that Garza had prior to taking Vioxx, one of the jurors failed to disclose that he had borrowed money from the widow in the suit, said Zipursky. "It's clear that this case, for any number of reasons, stands very little chance of ever coming back in favor of the plaintiff." But, don't expect this case to affect anything aside from a few other cases in Texas, says the law professor. Overwhelmingly, the settlement agreement will handle these cases and there's no reason to believe it won't keep moving forward, he says.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV